Best of the FDA committee meeting 10/15/2021



10/26/2021, 12:55:11 AM

The FDA committee remained unimpressed with quality and paucity of data for boosters use presented by Pfizer, Moderna and J&J but reluctantly gave approval for most at risk 65+ age group and immune compromised .

Targeted misleading media coverage creates confusion about efficacy, benefits and risks, what groups have recommendation for still unlicensed vaccine and boosters use as the CDC use expands beyond the FDA committee recommendation for 65+ Age group . As vaccinated transmit viral loads and are infectious as unvaccinated, post infection natural immunity is unacceptably unscientifically and politically not recognized by the governments and agencies in a push for illegal and harmful vaccine mandates , risk are dismissed benefit analysis also doesn’t support vaccine use in children and adults under 60year old including boosters use in these groups since vaccines don’t prevent transmission. while increasing risks of adverse effects such as myocarditis 5-10 times over risk of severe COVID-19 infection in children and young adults as well as embolism across all groups we discussed since 2020 The committee will meet in open session to discuss a request to amend Pfizer-BioNTech’s Emergency Use Authorization (EUA) for administration of their COVID-19 mRNA vaccine to children 5 through 11 years of age Where we expect this request not to get approval.

Gene expression regulation is another risk with mRNA platform use along with vaccines and modified nucleosides contribution to mutation rate amplification and creation of positive selective pressures